2494
G. Molteni et al. / Tetrahedron: Asymmetry 13 (2002) 2491–2495
3.5. General procedure for the cycloaddition between
hydrazonoyl chloride 8 and enantiopure 1,4-benzodi-
azepinones 1 and 2
3.3. Synthesis of N-prop-2-enyl-N-[(2S)-3,3-dimethyl-2-
butyl]-2-amino benzamide, 5b
A solution of 4b (2.60 g, 10.0 mmol) in ethanol (16 mL)
was treated with iron powder (4.47 g, 80 mmol) and
20% aqueous acetic acid (5.0 mL), and then heated
under reflux for 5 h under vigorous stirring. The mix-
ture was extracted with ethyl acetate (100 mL) and the
extract filtered through Celite. The organic layer was
washed firstly with 5% aqueous sodium hydrogencar-
bonate (60 mL), then with water (2×50 mL), and dried
over sodium sulfate. Evaporation of the solvent gave 5b
as undistillable oil (2.31 g, 89% yield); [h]2D5=+56.3 (c
0.78, CHCl3); IR (Nujol): 3450, 3350, 3245, 1620 cm−1;
1H NMR: l 1.00 (9H, s), 1.30 (3H, d, J=7.3), 4.20–
4.40 (5H, m), 5.00–5.80 (3H, m), 6.6–7.1 (4H, m); MS:
m/z 260 (M+). Anal. calcd for C16H24N2O: C, 73.81; H,
9.29; N, 10.76. Found: C, 73.77; H, 9.31; N, 9.34%.
A solution of 1 (1.36 g, 6.0 mmol) and 2 (5.0 mmol) in
dry dichloromethane (60 mL) was treated with base (see
Table 1) under stirring at room temperature for the
time indicated in Table 1. The undissolved material was
filtered off, the solvent was removed under reduced
pressure and the residue was chromatographed on a
silica gel column with ethyl acetate–hexane–
dichloromethane 12:4:1. First fractions contained
cycloadduct 10 or major 12, further elution gave
cycloadduct 11 or minor 13 (see Table 1).
Compound 10: mp 185°C (from diisopropyl ether);
[h]2D5=+79 (c 0.06, CHCl3); IR (Nujol): 1730, 1640
1
cm−1; H NMR (CDCl3): l 1.44 (3H, d, J=7.0), 1.57
(3H, s), 2.33 (3H, s), 3.70 (1H, d, J=14.7), 3.75 (3H, s),
4.58 (1H, d, J=14.7), 5.98 (1H, dd, J=8.1, 1.1), 6.08
(1H, q, J=7.0), 6.93 (1H, dd, J=8.1, 7.9), 7.1–7.5
(11H, m); 13C NMR (CDCl3): l 13.98 (q), 17.74 (q),
20.85 (q), 43.77 (t), 52.22 (d), 53.67 (q), 90.32 (s),
121.0–129.7, 133.68 (s), 137.36 (s), 139.51 (s), 168.56 (s),
173.77 (s); MS: m/z 468 (M+). Anal. calcd for
C28H28N4O3: C, 71.77; H, 6.02; N, 11.96. Found: C,
71.81; H, 6.05; N, 12.02%.
3.4. Synthesis of 2-methyl-4-[(S)-1-phenylethyl]-1,4-ben-
zodiazepin-5(3H)-one, 2a and 2-methyl-4-[(2S)-2,3,3-
trimethyl-2-butyl]-1,4-benzodiazepin-5(3H)-one, 2b
A solution of 5a or 5b (8.0 mmol) in 6 M aqueous
hydrochloric acid (6.0 mL) and acetic acid (3.0 mL) was
treated with sodium nitrite (1.10 g, 16.0 mmol) under
stirring and cooling at 0°C. After 30 min, the mixture
was treated with cold diethyl ether (35 mL) and sodium
azide (2.60 g, 0.04 mol) was added portionwise under
vigorous stirring and ice-cooling. After 1 h, the organic
layer was separated, washed with 5% aqueous sodium
hydrogencarbonate (25 mL), then with water (50 mL),
and dried over sodium sulfate. Evaporation of the
solvent gave crude 6a and 6b as brown oily residues,
which were used without further purification: 6a (2.52
g, 97%), IR (neat): 2120, 1660 cm−1; 6b (2.20 g, 96%) IR
(neat): 2130, 1650 cm−1.
Compound 11: mp 125°C (from diisopropyl ether);
[h]2D5=+7 (c 0.53, CHCl3); IR (Nujol): 1730, 1660 cm−1;
1H NMR (CDCl3): l 1.42 (3H, d, J=7.2), 1.62 (3H, s),
2.37 (3H, s), 3.68 (1H, d, J=15.0), 3.75 (3H, s), 4.38
(1H, d, J=15.0), 5.84 (1H, q, J=7.0), 7.0–7.4 (13H, m);
13C NMR (CDCl3): l 14.16 (q), 18.21 (q), 20.68 (q),
43.60 (t), 51.91 (d), 54.16 (q), 90.13 (s), 121.0–129.0,
133.27 (s), 137.20 (s), 140.11 (s), 167.59 (s), 172.98 (s);
MS: m/z 468 (M+). Anal. calcd for C28H28N4O3: C,
71.77; H, 6.02; N, 11.96. Found: C, 71.74; H, 5.99; N,
12.01%.
Compound 12a: mp 195°C (from diisopropyl ether);
[h]2D5=−6.3 (c 0.25, CHCl3); IR (Nujol): 1730, 1640
Crude 6a or 6b (7.8 mmol) were dissolved in toluene (30
mL) and then heated under reflux for 1 h. The solvent
was evaporated and the residue was crystallised from
diisopropyl ether affording pure 2a or 2b.
1
cm−1; H NMR (CDCl3): l 1.38 (3H, d, J=7.2), 1.43
(3H, s), 2.26 (3H, s), 2.86 (1H, d, J=16.0), 3.47 (1H, d,
J=16.0), 3.65 (3H, s), 6.13 (1H, q, J=7.2), 7.0–7.8
(13H, m); 13C NMR (CDCl3): l 17.13 (q), 20.43 (q),
22.35 (q), 50.84 (t), 52.06 (d), 52.32 (q), 92.75 (s), 115.17
(s), 127.1–131.9, 134.68 (s), 136.46 (s), 139.39 (s), 140.26
(s), 169.63 (s); MS: m/z 468 (M+). Anal. calcd for
C28H28N4O3: C, 71.77; H, 6.02; N, 11.96. Found: C,
71.73; H, 5.96; N, 11.94%.
Compound 2a: 1.52 g, 70%; mp 118°C; [h]2D5=−475 (c
1
0.50, CHCl3); IR (Nujol): 1635 cm−1; H NMR: l 1.50
(3H, d, J=7.2), 1.71 (3H, s), 3.25 (1H, d, J=14.5), 3.34
(1H, d, J=14.5), 6.19 (1H, q, J=7.2), 7.1–7.3 (7H, m),
7.42 (1H, dd, J=8.4, 1.3), 8.03 (1H, dd, J=8.4, 8.0);
MS: m/z 278 (M+). Anal. calcd for C18H18N2O: C,
77.67; H, 6.52; N, 10.06. Found: C, 77.62; H, 6.55; N,
10.10%.
Compound 13a: mp 125°C (from diisopropyl ether);
[h]2D5=+78 (c 0.45, CHCl3); IR (Nujol): 1730, 1645
1
cm−1; H NMR (CDCl3): l 1.57 (3H, s), 1.75 (3H, d,
Compound 2b: 1.41 g, 70%; mp 178°C; [h]2D5=−730 (c
J=7.0), 2.28 (3H, s), 3.35 (1H, d, J=16.6), 3.73 (3H, s),
3.80 (1H, d, J=16.6), 4.65 (1H, q, J=7.0), 6.9–7.8
(13H, m); 13C NMR (CDCl3): l 17.28 (q), 20.48 (q),
22.80 (q), 50.21 (t), 51.96 (d), 52.37 (q), 92.68 (s), 115.77
(s), 127.3–131.6, 134.59 (s), 136.80 (s), 138.91 (s), 140.36
(s), 168.38 (s); MS: m/z 468 (M+). Anal. calcd for
C28H28N4O3: C, 71.77; H, 6.02; N, 11.96. Found: C,
71.74; H, 6.05; N, 12.02%.
1
0.50, CHCl3); IR (Nujol): 1630 cm−1; H NMR: l 1.00
(9H, s), 1.30 (3H, d, J=7.5), 2.40 (3H, s), 3.50 (1H, d,
J=12.3), 3.75 (1H, d, J=12.3), 4.90 (1H, q, J=7.5),
7.15–7.25 (2H, m), 7.50 (1H, dd, J=8.3, 8.0), 7.96 (1H,
dd, J=8.3, 0.9); MS: m/z 258 (M+). Anal. calcd for
C16H22N2O: C, 74.38; H, 8.58; N, 10.84. Found: C,
74.34; H, 8.54; N, 10.76%.